Urovant Sciences Ltd

Urovant Sciences — Investor Presentation (May 2019)

34 slides from Urovant Sciences's investor presentation, May 13, 2019

  1. Slide 1: Urovant Sciences Corporate Presentation

    April 2019 UROVANT SCIENCES CORPORATE PRESENTATION Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements, including without limitation, statements related to: our plans to file for approval of vibegron with the FDA, and the timing of such filing and the likelihood of FDA approval; our ability to successfully develop Vibegron in the United States and

  3. Slide 3: Investment Highlights

    Vibegron: positive EMPOWUR Phase 3 results announced in March 2019 Achieved statistical significance in both co-primary endpoints and all seven key secondary endpoints with a favorable safety profile Potential best in class treatment option for OAB patients NDA filing planned by early 2020 Blockbust

  4. Slide 4: Late-Stage Pipeline in Urology

    LATE-STAGE PIPELINE IN UROLOGY Focused business development activities to support our vision of being a leading urology company Initial Target Areas: OAB (spectrum of care), Bladder Cancer, urology rare diseases and other urological conditions predominately treated by urologists DRUG CANDIDATE INDIC

  5. Slide 5: A Large, Well Defined Population

    A LARGE, WELL DEFINED POPULATION 1 Coyne et al., EpiLUTS 2007 2 Benner et al., J Urol 2009 3 IQVIA (IMS) NPA MAT 12 month Rx data ending Dec 2018 4 Systematic Review of the Burden of Illness in Overactive Bladder 5 Chancellor et al., Clin Therapies 2013 More than 30 million Americans over 40 years o

  6. Slide 6: Blockbuster OAB Branded Launches Have Occurred Every Six Years

    BLOCKBUSTER OAB BRANDED LAUNCHES HAVE OCCURRED EVERY SIX YEARS SINCE LAUNCH OF DETROL IN 1998 Strong Revenues for New OAB Entrants (with Incremental Differentiation) in a High Churn Market Vibegron Potential in a High Churn Market Potential for better safety/tolerability than ACH category EMPOWUR Ph

  7. Slide 7: Vibegron Clinical Data and Development

    VIBEGRON CLINICAL DATA AND DEVELOPMENT

  8. Slide 8: Extensive Clinical Development Program

    EXTENSIVE CLINICAL DEVELOPMENT PROGRAM In-licensed from Merck in February 2017 >3,200 subjects dosed with vibegron to date Three successful large, placebo control studies completed in over 4,000 patients achieving all primary and secondary endpoints Robust clinical pharmacology package (17 studies c

  9. Slide 9: Potential Points of Differentiation

    POTENTIAL POINTS OF DIFFERENTIATION1 ACH Highly selective for human β3 receptor3 Rapid onset of efficacy at 2 weeks Potential efficacy claim for urgency4 Potential broader efficacy claims No CYP2D6 drug-drug interactions No QTc signal Single convenient crushable dose5 No known dementia risk6 Vibegro

  10. Slide 10: Vibegron is a highly selective β3 agonist

    1 Data on file. Activity shown as a percentage of control activity (β1, β3 – isoproterenol; β2 – procaterol) β3 AR: Most highly expressed adrenergic receptor in bladder detrusor muscle β3 stimulation leads to relaxation of bladder detrusor muscle, increasing capacity and reducing symptoms of OAB wit

  11. Slide 11: Lack of Clinically Significant Drug-Drug Interactions

    LACK OF CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTIONS Mirabegron 1 Zanger et al. Pharmacology & Therapeutics 2013 2 IQVIA (IMS) Patient Rx/Dx Claims Analysis March 2014-Septeember 2017 Vibegron, unlike mirabegron, does not inhibit the CYP2D6 enzyme CYP2D6 accounts for approximately 20% of clinically

  12. Slide 12: Phase 3 Trial Design

    POPULATION Women and men with OAB wet or dry DURATION 12-week treatment period plus 40-week extension KEY ENDPOINTS Co-primary endpoints: Change from baseline in daily number of (1) micturitions and (2) urge urinary incontinence episodes Primary analysis: vibegron vs placebo (powered); tolterodine –

  13. Slide 13: EMPOWUR Results: Strong Efficacy Across All OAB Endpoints

    EMPOWUR RESULTS: VIBEGRON DEMONSTRATED STRONG EFFICACY ACROSS ALL OAB ENDPOINTS Endpoint Vibegron n p-value UUI Episodes2 -0.6 383 <0.0001 Micturitions2 -0.5 492 <0.001 Urgency Episodes3 -0.7 492 0.0020 Total Incontinence Episodes3 -0.7 383 <0.0001 Volume Voided (ml)3 21.2 490 <0.0001 OAB-q Coping S

  14. Slide 14: Rapid Onset and Sustained Benefit in Phase 3 Trial

    Table 14.2.2.1.2, Full Analysis Set for Incontinence, CFB Least squares mean Covariates included in the mixed model for repeated measures are study visit, sex, region, baseline number of UUI, and treatment by study visit interaction. , *** *** *** *** P-value is vibegron vs placebo P-value: ***<0.00

  15. Slide 15: >50% of Patients Achieved a 75% Reduction in UUI Episodes

    P-value is active vs placebo P-values: *<0.05, **<0.01, ***<0.001 Table 14.2.4.1.1 Full Analysis Set for Incontinence. 75% Reduction in UUI from Baseline at Week 12 Table 14.2.5.1.1 Full Analysis Set for Incontinence 100% Reduction in UUI from Baseline at Week 12 Table 14.2.6.1.1 Full Analysis Set 5

  16. Slide 16: Vibegron Phase 3 and Mirabegron Phase 3 Results

    Vibegron P-values: *<0.05, **<0.01, ***<0.001 Mirabegron1 1Data from trial ‘074, except for 50 mg micturitions, total incontinence, and volume voided which is averaged from trials ‘046, ‘047, and ‘074; trials ‘046 and ‘047 did not test the 25 mg dose. For averaged effect sizes, the highest level of

  17. Slide 17: Vibegron 75mg EMPOWUR and Mirabegron CAPRICORN

    VIBEGRON 75MG EMPOWUR AND MIRABEGRON 25MG/50MG CAPRICORN The below is not a head-to-head trial. These trials were conducted at different points in time using different trial designs. All data are presented as change from baseline (active – placebo) Endpoint (Week 12) 75 mg Vibegron Micturitions -0.5

  18. Slide 18: Most Common Adverse Events Consistent with Placebo

    Table 14.3.1.15, Safety Analysis Set. Represents number of patients. AE term n (%) Placebo N=540 Vibegron N=545 Tolterodine N=430 Headache 13 (2.4) 22 (4.0) 11 (2.6) Nasopharyngitis 9 (1.7) 15 (2.8) 11 (2.6) Diarrhea 6 (1.1) 12 (2.2) 9 (2.1) Nausea 6 (1.1) 12 (2.2) 5 (1.2) MOST COMMON ADVERSE EVENTS

  19. Slide 19: Selected Key Adverse Events

    AE term n (%) Placebo N=540 Vibegron N=545 Tolterodine N=430 Hypertension 9 (1.7) 9 (1.7) 11 (2.6) Blood pressure increased 5 (0.9) 4 (0.7) 8 (1.9) Tachycardia 0 0 1 (0.2) Hypotension 1 (0.2) 1 (0.2) 1 (0.2) Dizziness 6 (1.1) 5 (0.9) 4 (0.9) Urinary tract infection 33 (6.1) 27 (5.0) 25 (5.8) Urinary

  20. Slide 20: Vibegron is a Potential Best in Class Treatment Option for OAB Patients

    VIBEGRON IS A POTENTIAL BEST IN CLASS TREATMENT OPTION FOR OAB PATIENTS PHASE 3 RESULTS Strong efficacy results delivered with a once daily 75mg convenient dose Vibegron achieved co-primary endpoints demonstrating statistically significant reduction in daily micturitions and daily urge urinary incon

  21. Slide 21: OAB Treatment Paradigm

    OAB TREATMENT PARADIGM

  22. Slide 22: Current Treatment Paradigm

    CURRENT TREATMENT PARADIGM: Clinical guideline prior to Rx Limited choice of toxin or intensive surgical therapy Limited incremental efficacy 86% start on ACH4 71% fail ACH within 6 months5 72% discontinue oral therapy within one year4 1 Benner et al., J Urol, 2009 2 IQVIA (IMS) New to Brand Data 20

  23. Slide 23: β3 Agonists Represent the Next Wave of Blockbuster Therapies in OAB

    β3 AGONISTS REPRESENT THE NEXT WAVE OF BLOCKBUSTER THERAPIES IN OAB Annual brand sales of ~$2.6 billion2 β3 agonist continues to take share from ACHs (17%+ US TRx growth in 2018)1 FY2018 β3 agonist net sales in the Americas expected to exceed $800 million (+23% y/y)3 Over 18 Million Prescriptions Wr

  24. Slide 24: Anticholinergic Use Associated with Cognitive Impairment and Dementia

    ANTICHOLINERGIC USE ASSOCIATED WITH COGNITIVE IMPAIRMENT AND DEMENTIA “Higher cumulative anticholinergic use is associated with an increased risk for dementia. Efforts to increase awareness among health care professionals and older adults about this potential medication-related risk are important to

  25. Slide 25: Our Commercial Strategy

    OUR COMMERCIAL STRATEGY

  26. Slide 26: URO, NPPA, and Long Term Care

    Urologists/Uro-NPPAs prescribe ~5 million OAB RXs annually and UROs prescribe 31% of all B3 agonist RXs2 UROs account for $1.4 billion of total market potential2 Managed efficiently with approximately 100 FTE’s3 LTC highly specialized market requiring expertise and experience LTC accounts for $1.2 b

  27. Slide 27: US OAB Market: Pricing and Coverage

    US OAB MARKET: PRICING AND COVERAGE Oral OAB category is not highly managed by payors1 Branded OAB drugs are well covered: 95% of commercial plans and 100% of Medicare plans cover Myrbetriq2 Branded agents continue to have pricing elasticity Myrbetriq, Vesicare, and Toviaz increased prices by 9%, 9%

  28. Slide 28: Establish Vibegron as the OAB Brand of Choice

    ESTABLISH VIBEGRON AS THE OAB BRAND OF CHOICE Commercial leadership intends to build a best-in-class urology and PCP sales force with the following advantages: Potential key points of label differentiation Issues with ACH treatments Franchise with potential additional indications and new products Su

  29. Slide 29: Growth Opportunities

    GROWTH OPPORTUNITIES

  30. Slide 30: OAB in Men with BPH and IBS-Associated Pain Lifecycle Opportunities

    OAB IN MEN WITH BPH AND IBS-ASSOCIATED PAIN REPRESENT LIFECYCLE OPPORTUNITIES WITH SIGNIFICANT MARKET POTENTIAL 40 million Men aged 50 – 80 years old with BPH >4 million Treated BPH patients in the U.S. >2 million U.S. BPH patients with co-morbid OAB LIFECYCLE GROWTH OPPORTUNITIES: VIBEGRON OAB IN M

  31. Slide 31: DNA Gene Therapy Overview

    DNA GENE THERAPY OVERVIEW Clinical Summary Plasmid vector that exerts effect by expressing the pore-forming subunit of the Maxi-K ion channel to reduce excitability of detrusor smooth muscle cells Studied in two Phase 1 clinical trials in the US in a total of 22 women with OAB Phase 1b clinical tria

  32. Slide 32: Balance Sheet Highlights

    BALANCE SHEET HIGHLIGHTS $85.4 million cash as of March 31, 2019* $100 million credit facility with Hercules Capital $85 million capital draw left on the facility as of March 31, 2019 $30 million accessible through September 30, 2019 as a result of positive phase 3 EMPOWUR data UROVANT SCIENCES * Pr

  33. Slide 33: Urovant Sciences Milestones

    2020 Submit NDA for vibegron in OAB (early 2020) Top-line results of vibegron trial in IBS-associated pain Top-line results of URO-902 trial in second half 2020 Top-line results of vibegron trial in OAB and BPH UROVANT SCIENCES MILESTONES 2018Begin enrollment of the Phase 3 vibegron trial in OAB In-

  34. Slide 34: Vibegron: Positive EMPOWUR Phase 3 Results Announced in March 2019

    Vibegron: positive EMPOWUR Phase 3 results announced in March 2019 Achieved statistical significance in both co-primary endpoints and all seven key secondary endpoints with a favorable safety profile Potential best in class treatment option for OAB patients NDA filing planned by early 2020 Blockbust

Urovant Sciences — Investor Presentation (May 2019) on 6ix